\n<\/p>\n
A nationwide recall of Xanax has many people wondering whether their anti-anxiety medication has been affected.<\/p>\n<\/div>\n
According to an Enforcement Report issued by the Food and Drug Administration (FDA)<\/a>, Viatris, Inc., a major pharmaceutical company, has voluntarily recalled a specific lot of Xanax XR<\/a> (alprazolam extended-release tablets) distributed across the United States.<\/p>\n<\/div>\n The recall, initiated on March 17, affects 3-milligram tablets packaged in 60-tablet bottles, produced in Ireland and distributed by Viatris Specialty LLC in Morgantown, W.Va. <\/p>\n<\/div>\n The decision comes after the product failed to meet dissolution specifications, which are critical for ensuring proper drug release and effectiveness. <\/p>\n<\/div>\n Patients and healthcare providers are urged to check their medication and contact Viatris or their healthcare professional if they have the affected lot, numbered 8177156, with an expiration date of February 28, 2027. <\/p>\n<\/div>\n<\/div>\n Dissolution testing measures how quickly and efficiently the active ingredient is released from the tablet into the body. <\/p>\n<\/div>\n As noted in the Enforcement Report, the formulation of the drug being recalled is Xanax XR, a medication commonly prescribed for the treatment of anxiety and panic disorders.<\/p>\n<\/div>\n This extended-release formulation is designed to release the medication gradually over time, providing more consistent symptom control. <\/p>\n<\/div>\n Aleksey Aronov<\/a>, AGPCNP-BC, a board certified adult geriatric primary care nurse practitioner and the founder and CEO of VIPs IV, told Healthline that if the pill does not meet dissolution specifications, it may not break down as it should in the body, which could result in the medicine not working properly.<\/p>\n<\/div>\n \u201cWhen a pill does not dissolve the right way, the body may not absorb the correct amount of the medicine, which may result in not treating anxiety or panic symptoms appropriately,\u201d he said. \u201cPills that fail to dissolve essentially may not be effective.\u201d<\/p>\n<\/div>\n The Enforcement Report further notes that the recall is classified by the Aronov clarified this description further by explaining that failed dissolution is not a safety hazard, nor will the drug cause harm to your body.<\/p>\n<\/div>\n \u201cIt is just a quality control issue that may result in the patient not benefiting from the medicine when they take it,\u201d he said.<\/p>\n<\/div>\n <\/div>\n People taking Xanax should speak with their doctor about getting a replacement prescription, Aronov said.<\/p>\n<\/div>\n \u201cPatients should not abruptly stop taking Xanax because this medicine requires a very gradual taper in order to prevent withdrawal symptoms,\u201d he said.<\/p>\n<\/div>\n Roger Flugel<\/a>, chief scientific officer for Neurogan Health, emphasized that patients using this drug \u201cshouldn\u2019t panic.\u201d<\/p>\n<\/div>\n Firstly, it\u2019s only the 3-milligram tablets of Xanax XR in 60-tablet bottles identified by the lot number 8177156 that are affected, he said.<\/p>\n<\/div>\n \u201cIt\u2019s important that you know the lot number before anything else, and see to it that you take the necessary steps,\u201d said Flugel.<\/p>\n<\/div>\n Even if you have this lot number, he explained that you aren\u2019t in any imminent danger since any health effects are temporary and reversible.<\/p>\n<\/div>\n \u201cMy advice is that you shouldn\u2019t abruptly stop taking it, even when the lot number [of the] medication matches the one above, as that can be riskier,\u201d Flugel said.<\/p>\n<\/div>\n Instead, continue to take your medication as directed and speak with your doctor right away about your concerns.<\/p>\n<\/div>\n No press release has been issued by the FDA for this recall, and the recall remains ongoing as of the latest available data from April 8, 2026. <\/p>\n<\/div>\n Consumers and healthcare professionals can stay informed by monitoring the